Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct 12;64(2):124–131. doi: 10.1093/cid/ciw683

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

PMC Copyright notice

Figure 1. — Inflammatory biomarker levels in human immunodeficiency virus (HIV)–uninfected participants from Thailand (black dots); in participants with acute HIV infection diagnosed in fourth-generation stage 1 (4thG1; blue), stage 2 (4thG2; green), or stage 3 (4thG3; red); and in participants with chronic untreated HIV infection (purple). A–E, Plasma biomarker levels at study entry before starting antiretroviral therapy (ART), including C-reactive protein (CRP) (A), tumor necrosis factor (TNF) (B), interleukin 6 (IL-6) (C), soluble IL-6 receptor (sIL-6R) (D), and soluble gp130 (sgp130) (E). Horizontal bars represent median values. F–J, Changes in the same plasma biomarker levels over 96 weeks of ART initiated during acute HIV infection. Purple dashed line represents median biomarker level in participants during treated chronic HIV infection; black dotted lines, median biomarker levels in HIV-uninfected participants from Thailand. ^† P < .05 for comparison with treated chronically HIV-infected participants; *P < .05 for comparison with HIV-uninfected participants. Median values are shown with interquartile range bars.